Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Tofacitinib in Systemic Lupus Erythematosus
NCT02535689Phase 1Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Aug 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tofacitinib oral solution in systemic lupus erythematosus (SLE) (3 arms), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoint: Safety and tolerability of tofacitinib at 5 years. Started Aug 2015; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02535689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535689.